Published in Cancer Weekly, January 11th, 2005
Under the terms of the agreement, CTI has development and commercialization rights to the compounds. At the same time, Roche has granted CTI a worldwide license for bisplatinum compounds under its patents. Both agreements foresee certain milestone payments and royalties on future sales of the drugs.
"Bisplatinum compounds are part of an important class of anticancer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.